Publications by authors named "M Murakawa"

Purpose: Reports on the association of perioperative nutritional and inflammatory status with the clinical course of adjuvant chemotherapy did not include neoadjuvant chemotherapy. We aimed to clarify the mechanism by which perioperative nutritional and inflammatory status affect the clinical course of postoperative adjuvant chemotherapy in patients with pancreatic cancer.

Methods: We enrolled 123 patients with pancreatic cancer retrospectively who underwent surgical resection with neoadjuvant and S-1 adjuvant chemotherapy between January 2013 and December 2022.

View Article and Find Full Text PDF

Purpose: The C-reactive protein-albumin-lymphocyte (CALLY) index, which simultaneously evaluates the nutritional, immunological, and inflammatory statuses, is a new prognostic biomarker in patients with various cancers; however, no study has reported the clinical significance of the CALLY index in patients with pancreatic cancer. This study aimed to investigate whether the preoperative CALLY index is a prognostic biomarker in patients undergoing surgical resection of pancreatic cancer.

Methods: We retrospectively enrolled 461 patients with pancreatic cancer who underwent surgical resection between January 2013 and December 2022.

View Article and Find Full Text PDF

Background & Aims: Hepatitis B virus (HBV)-DNA integration into the host genome contributes to hepatocellular carcinoma (HCC) development. KMT2B is the second most frequent locus of HBV-DNA integration in HCC; however, its role and function remain unclear. We aimed to clarify the impact of HBV-KMT2B integration in HCC development using a human genome-edited induced pluripotent stem cell (iPSCs) model.

View Article and Find Full Text PDF
Article Synopsis
  • * Out of 159 patients evaluated, over half experienced loss of skeletal muscle mass during neoadjuvant chemotherapy, which correlated with a significantly lower completion rate of S-1 adjuvant chemotherapy.
  • * The findings suggest that addressing skeletal muscle loss during neoadjuvant chemotherapy could enhance the continuation of adjuvant treatment and potentially improve survival rates in these patients.
View Article and Find Full Text PDF